Role of preoperative hematological markers in carcinoma breast and its efficacy in correlation with clinicopathological staging – a novel technique

Abstract

Carcinoma breast ranks second globally in terms of cancer-related deaths among women and is the most common disease diagnosed in women. The breasts are superficially situated glandular structures that fluctuate in size and density over the pectoralis major muscle. They consist of milk-producing cells arranged into lobules, which are grouped into lobes interspersed with fatty tissue. Milk is produced in the acini and transferred by lactiferous ducts that connect to the nipple. The breasts are supported by Cooper's ligaments, which anchor them to the underlying muscle fascia . The ductal epithelium(ductal carcinoma) is where the majority of carcinoma breast begin, though some arise from the lobules (lobular carcinoma). Carcinoma breast risk factors are many and well-established. In Western countries, widespread screening programs have led to early detection, often before symptoms appear. Conversely, in many developing countries, symptoms such as a palpable breast lump or abnormal nipple discharge are common presenting complaints3. Diagnosis typically involves a physical exam, tissue biopsy. Treatment may include surgery, chemotherapy, radiation, hormone more recently, immunotherapy. Decisions regarding treatment are tailored to the individual, basedon factors such as tumour histology, stage, molecular markers, and genetic mutations. Even with breakthroughs in early detection and dozens of novel therapeutic choices, carcinoma breast remains the most common tumour in females. It is a multifaceted illness with a range of biomolecular subgroups and clinical presentations. It has taken significant work to categorize this carcinoma according to its molecular makeup, and treatment regimens are currently defined by subtype. These are typically chosen after surgery, though. Chronic inflammation and cancer have a complicated and reciprocal interaction. In this investigation, we concentrate on how inflammation contributes to the growth of breast cancer. It is now commonly known that the characteristics of the tumour do not determine the fate for cancer patients alone, but that inflammation linked to cancer plays a crucial role in the development and prognosis of most cancers Systemic changes associated with the inflammatory response include an elevated neutrophil count and a modest increase in platelet count. Systemic inflammatory markers have just recently been made available as trustworthy and simple prognostic indicators. Tumour characteristics such as size, histological grade, lymph node involvement, ER, PR status and HER2NEU status are important prognostic indicators. Recently, gene expression profiling has emerged as a valuable tool to further stratify risk, inform therapy choices, especially for breast cancer that has hormone receptors, where it can help determine the need for chemotherapy. Liquid biopsy assays that detect circulating tumour cells have also entered the field of prognosis for early-stage and locally advanced breast cancer10. But these tests are frequently expensive, experimental, and not commonly accessible in standard healthcare settings.